Home›Stock Screener›Dipna Pharmachem

Dipna Pharmachem Share Price Today | Stock Price & Dipna Pharmachem Share Screener

DPL Pharmaceuticals & Biotechnology

Track the current Dipna Pharmachem share price and stock price live with TickJournal's free stock screener. Track DPL market cap trends to gauge the company's total market size. Use the Dipna Pharmachem stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Dipna Pharmachem opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹134 and net income of ₹2, with EBITDA of ₹5, an operating margin of 3.0% and a profit margin of 1.5%.

Dipna Pharmachem Market Cap ₹10.76 Cr.
DPL P/E Ratio (TTM) 4.50
Dipna Pharmachem P/B Ratio 0.18
EPS (TTM) ₹1.00
Dividend Yield -
Debt to Equity 0.48
DPL 52 Week High -
Dipna Pharmachem 52 Week Low -
Operating Margin 3.00%
Profit Margin 1.49%
DPL Revenue (TTM) ₹134.00
EBITDA ₹5.00
Net Income ₹2.00
Total Assets ₹206.00
Total Equity ₹62.00

Dipna Pharmachem Share Price Chart

Track the current stock price of Dipna Pharmachem with an interactive chart. Analyse DPL share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Dipna Pharmachem stock quote in one place.

Dipna Pharmachem Company Profile - Fundamental Screener

Screen Dipna Pharmachem company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for DPL shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE0MC401013.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE0MC401013

Dipna Pharmachem Balance Sheet Screener

Screen DPL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹206, up from ₹132 in 2025.

Latest statistics put total assets at ₹206 and shareholder funds at ₹62, with a leverage ratio of 0.48.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018

Assets

Total Assets 206 132 133 78 36 25 18 14 11
Current Assets 0 0 0 0 0 0 0 0 0
Fixed Assets 0 0 0 0 0 0 0 0 0

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0
Current Liabilities 10 9 13 11 6 4 0 0 0
Non-Current Liabilities 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 62 39 38 24 2 1 1 1 1
Share Capital 26 24 24 12 0 0 0 0 0
Reserves & Surplus 36 14 14 12 2 1 1 1 0

Dipna Pharmachem Income Statement Screener - Profit & Revenue Analysis

Screen Dipna Pharmachem income statement and profit fundamentals. Analyze DPL quarterly results. Dipna Pharmachem reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For None-None, revenue was ₹134 and net profit was ₹2, equal to earnings per unit of ₹1.00, at an operating margin of 3%.

In that period expenses were ₹129, interest cost ₹2 and tax ₹1. The next period listed, 2026-March, shows revenue of ₹129 and net profit of ₹3.

Item None-None 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March

Revenue and Expenses

Revenue 134 129 125 164 100 73 31 31 20 17
Expenses 129 124 122 161 98 71 31 31 20 17

Operating Costs and Margins

EBITDA 5 5 3 3 2 2 0 0 0 0
Operating Profit % 3.00% 4.00% 3.00% 2.00% 2.00% 3.00% 1.00% 0.00% 0.00% 0.00%
Depreciation 0 0 0 0 0 0 0 0 0 0
Interest 2 1 2 2 1 1 0 0 0 0

Profit and Earnings

Profit Before Tax 3 4 1 1 1 2 0 0 0 0
Tax 1 1 0 0 1 0 0 0 0 0
Net Profit 2 3 1 1 1 1 0 0 0 0
EPS 1.00 1.00 0.41 0.45 0.76 333.39 6.91 16.86 9.15 17.27

Dipna Pharmachem Cash Flow Screener - Liquidity Fundamentals

Screen DPL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2025-March, operating activities used ₹9, and net cash flow was an outflow of ₹13.

Over the same period, investing activities provided ₹0 and financing activities used ₹4.

Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March

Cash from Operations and Investing

Operating Activities -9 -5 -21 3 -2 -3
Investing Activities 0 0 0 0 0 0

Financing and Net Cash

Financing Activities -4 14 27 -3 3 3
Net Cash Flow -13 8 6 0 0 0

Dipna Pharmachem Shareholding Pattern Screener

See Dipna Pharmachem shareholding pattern with promoter, FII, and DII holdings. Check Dipna Pharmachem promoter holding and ownership changes for DPL on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 9.13%, foreign institutions 0.00%, domestic institutions 0.00% and the public 79.16%, spread across 1,717 shareholders.

The shareholder count was 1,717 in 2026-Mar, compared with 1,788 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Sept 2025-Nov 2024-Mar 2024-Sept

Promoter Holding

Promoter Holding 9.13% 9.13% 9.13% 9.98% 9.98% 9.13% 9.98% 9.98%

Institutional Investors

FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 79.16% 81.17% 82.70% 71.21% 73.74% 79.11% 63.07% 81.82%
Other Holding 11.71% 9.71% 8.18% 18.81% 16.28% 11.76% 26.95% 8.20%
Shareholder Count 1,717 1,788 1,896 1,997 1,742 1,741 1,807 2,652

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Dipna Pharmachem. Dipna Pharmachem dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Dipna Pharmachem.

Dipna Pharmachem Stock Index Membership - Nifty & Sensex

See which indices include Dipna Pharmachem stock. Check DPL index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Dipna Pharmachem is not part of any tracked indices.
Only major market indices are tracked in our system.

Dipna Pharmachem Market Events Screener - Corporate Actions

Get Dipna Pharmachem corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Dipna Pharmachem stock events that may affect DPL share price, along with derivatives, futures and options activity and sector gainers.

10 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 4, 2026, with a record date of November 4, 2026.

It is followed by Quarterly Result Announcement dated July 2, 2026 and Quarterly Result Announcement dated November 26, 2025.

Announcement Date Record Date Event Type Information Price Impact
2026-11-04 2026-11-04 Quarterly Result Announcement NA 2.04%
2026-07-02 2026-07-02 Quarterly Result Announcement NA -9.72%
2025-11-26 2025-11-26 Quarterly Result Announcement NA -10.55%
2025-08-30 2025-08-30 Annual General Meeting NA -5.94%
2025-07-07 2025-07-07 Quarterly Result Announcement NA 3.65%
2025-04-04 2025-04-04 Extraordinary General Meeting NA 10.31%
2024-12-11 2024-12-11 Quarterly Result Announcement NA 0.00%
2024-08-27 2024-08-27 Annual General Meeting NA 15.01%
2024-02-12 2024-02-12 Rights 13:12 27.52%
2024-01-03 2024-01-03 Extraordinary General Meeting NA -10.98%

Dipna Pharmachem Competitors Screener - Peer Stocks Comparison

Screen DPL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,676 40.80 61,674 12.69% 11,565 60.46
Divis Laboratories 295,997 87.70 11,067 13.95% 2,568 68.76
Torrent Pharmaceuticals 177,586 85.00 13,886 20.34% 2,138 47.23
Laurus Labs 126,325 89.90 6,868 22.01% 890 57.04
Zydus Life Science 120,119 27.60 27,658 17.64% 5,026 55.91
Dr Reddys Laboratories 115,854 41.80 35,059 3.90% 4,158 71.26
Cipla 112,131 39.50 29,045 2.24% 3,870 53.06
Mankind Pharma 107,805 47.90 14,636 14.85% 1,938 61.37
Aurobindo Pharma 103,229 25.80 34,145 5.56% 3,503 60.39
Lupin 89,172 17.30 29,039 26.75% 5,356 39.39

Dipna Pharmachem Company Announcements - News & Reports Screener

Screen DPL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated .

The next most recent announcements are dated November 4, 2026 and November 4, 2026.

Date Update Actions
Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-04 Integrated Filing (Finance) For The Quarter Ended On 30Th June 2026 -
2026-11-04 Outcome Of Board Meeting Held Today I.E. 4Th November 2026 -
2026-11-04 Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. 4Th November 2026 -
2026-11-03 Reconstitution Of The Committee -
2026-11-03 Announcement under Regulation 30 (LODR)-Change in Directorate -
2026-11-03 Board Meeting Outcome for Outcome And Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-10-31 Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Wednesday 4Th November 2026 -
2026-10-24 Outcome And Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-10-24 Announcement under Regulation 30 (LODR)-Resignation of Director -
2026-10-24 Announcement under Regulation 30 (LODR)-Change in Directorate -
2026-10-24 Board Meeting Outcome for Outcome And Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-10-23 Appointment of Company Secretary and Compliance Officer -
2026-10-23 Board Meeting Outcome for Outcome And Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-10-19 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-09-30 Closure of Trading Window -
2026-07-15 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-07-06 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-07-02 Submission Of Integrated Financials -
2026-07-02 Submission Of Statement Of Deviation And Variation -

Frequently Asked Questions

How is the company valued right now?

The P/E ratio is 4.50 and the P/B ratio is 0.18, with earnings per unit of ₹1.00. Market capitalisation stands at ₹10.76 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Key statistics were last updated on November 19, 2026. This page covers 9 balance sheet periods, 10 income statement periods, 6 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.